This activity is expired and is no longer available for CME credit.


Advances in the Immunopathogenesis of Rheumatic Diseases: Lessons from Checkpoint Immunotherapy of Cancer

Author(s)/Faculty: Leonard H. Calabrese, DO
Release Date: 10/31/2017Expiration Date: 10/31/2019
Credit Type: CMENumber of Credits: 0
Content Type: ArticleProvider:
Rheumatoid arthritis (RA) is a progressive and painful systemic inflammatory disease that preferentially attacks the synovium of the joints, leading to joint destruction, debility, and deformity. Increased understanding of the underlying pathophysiology of RA has made a remarkable difference in its treatment and prognosis. Numerous therapeutic agents with diverse targets and mechanisms have been added to the RA armamentarium, allowing for intervention at various stages in the pathogenic process of the disease. By understanding the underlying immunologic mechanisms driving RA progression, clinicians involved in the management of patients with RA will be better equipped to evaluate the clinical and pharmacologic safety, as well as the efficacy profiles of current and emerging therapies. This activity will review advances in the immunopathogenesis of rheumatic diseases and lessons from checkpoint immunotherapy of cancer.